Want to see JP:4597 full AI Analyst Report?
4597 Stock Chart & Stats
¥27.00
¥0.00(0.00%)
At close: 4:00 PM EST
¥27.00
¥0.00(0.00%)
Day’s Range― - ―
52-Week Range¥21.00 - ¥42.00
Previous CloseN/A
Volume8.51M
Average Volume (3M)60.71M
Market Cap
¥7.37B
Enterprise Value¥5.89B
Total Cash (Recent Filing)¥1.29B
Total Debt (Recent Filing)¥78.00M
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.33
Shares Outstanding273,414,370
10 Day Avg. Volume75,143,938
30 Day Avg. Volume60,706,242
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)3.93
Price to Sales (P/S)16.06
P/FCF Ratio-8.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2
Revenue Forecast (FY)¥1.92B
Bulls Say, Bears Say
Bulls Say
Conservative LeverageDebt-to-equity of about 0.05 indicates limited reliance on borrowing, reducing near-term interest and refinancing pressure. This gives Solasia more balance-sheet flexibility to pursue oncology development and partnerships while it works toward improving profitability.
Improved Gross MarginThe return to a positive gross margin suggests Solasia’s products or partnered commercial activities are generating economic value before operating costs. If maintained, this improvement could provide a foundation for better operating leverage as revenue scales.
Licensing And Collaboration ModelA licensing and collaboration-led model gives Solasia multiple contractual routes to monetize candidates or approved products, including milestone, royalty, profit-share, and reimbursement income. This supports commercialization through partners if development and regulatory objectives are achieved.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow means the business is not currently funding its activities internally. Continued cash consumption can increase dependence on future financing, potentially reducing strategic flexibility and creating dilution risk if the pattern persists.
Deep Ongoing LossesPersistent losses and a net margin near -217% show that the current cost base remains far above revenue generation. Without clear operating leverage, Solasia may struggle to convert product progress or partnerships into sustainable earnings over the next several quarters.
Revenue Volatility And DeclineVolatile revenue and a recent TTM decline make the company’s commercial trajectory difficult to sustain and forecast. Uneven sales can limit milestone and royalty visibility, while weaker top-line performance makes it harder to absorb fixed development and operating costs.
Solasia Pharma KK News
4597 FAQ
What was Solasia Pharma KK’s price range in the past 12 months?
Solasia Pharma KK lowest stock price was ¥21.00 and its highest was ¥42.00 in the past 12 months.
What is Solasia Pharma KK’s market cap?
Solasia Pharma KK’s market cap is ¥7.37B.
When is Solasia Pharma KK’s upcoming earnings report date?
Solasia Pharma KK’s upcoming earnings report date is Nov 12, 2026 which is in 16 days.
How were Solasia Pharma KK’s earnings last quarter?
Solasia Pharma KK released its earnings results on Aug 13, 2026. The company reported -¥1 earnings per share for the quarter.
Is Solasia Pharma KK overvalued?
According to Wall Street analysts Solasia Pharma KK’s price is currently Overvalued.
Does Solasia Pharma KK pay dividends?
Solasia Pharma KK does not currently pay dividends.
What is Solasia Pharma KK’s EPS estimate?
Solasia Pharma KK’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Solasia Pharma KK have?
Solasia Pharma KK has 273,414,370 shares outstanding.
What happened to Solasia Pharma KK’s price movement after its last earnings report?
Solasia Pharma KK reported an EPS of -¥1 in its last earnings report. Following the earnings report the stock price went up 3.333%.
Which hedge fund is a major shareholder of Solasia Pharma KK?
Currently, no hedge funds are holding shares in JP:4597
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Solasia Pharma KK
Established in 2006 and headquartered in Tokyo, Japan, Solasia Pharma K.K. is dedicated to the development and commercialization of oncology treatments throughout Japan and other parts of Asia. The company's marketed products include SP-03 (episil oral liquid), designed for the protection and relief of oral pain and inflammation (mucositis/stomatitis) resulting from cancer chemotherapy and radiation. Additionally, they offer SP-01 (Sancuso), a transdermal patch that delivers granisetron, an anti-emetic, into the bloodstream to manage chemotherapy-induced nausea and vomiting. Solasia Pharma's development pipeline features SP-02 (Darinaparsin), a mitochondrial-targeted agent that has successfully completed Phase III clinical trials for a range of hematologic and solid cancers. Also in Phase III clinical study is SP-05 (Arfolitixorin), which aims to bolster the anti-tumor effectiveness of fluorouracil in various cancers, including pancreatic, breast, stomach, and head and neck cancers. In its pre-clinical stage, SP-04 is being developed to address chemotherapy-induced peripheral neuropathy.
Technical Analysis
Nippon Chemiphar Co., Ltd.
―
Taiko Pharmaceutical Co., Ltd.
―
Symbio Pharmaceuticals Limited
―
Modalis Therapeutics Corporation
―
Cyfuse Biomedical K.K.
―